Citations - Wimberger Pauline

No abstract... Read more
Published on: 2020-09-25
Source: Wimberger Pauline
By: COVIDSurg Collaborative
No abstract... Read more
Published on: 2020-09-25
Source: Wimberger Pauline
By: COVIDSurg Collaborative
No abstract... Read more
Published on: 2020-09-25
Source: Wimberger Pauline
By: COVIDSurg Collaborative
CONCLUSIONS: In clinical practice, CDK4/6i + ET has been rapidly implemented. A group of patients with a more unfavorable prognosis was possibly treated in the real-world setting than in the reported randomized clinical trials. The available data suggest that longer follow-up times and a larger sample size are required in... Read more
Published on: 2020-09-21
Source: Wimberger Pauline
By: Andreas Schneeweiss
CONCLUSIONS: In clinical practice, CDK4/6i + ET has been rapidly implemented. A group of patients with a more unfavorable prognosis was possibly treated in the real-world setting than in the reported randomized clinical trials. The available data suggest that longer follow-up times and a larger sample size are required in... Read more
Published on: 2020-09-21
Source: Wimberger Pauline
By: Andreas Schneeweiss
CONCLUSIONS: In clinical practice, CDK4/6i + ET has been rapidly implemented. A group of patients with a more unfavorable prognosis was possibly treated in the real-world setting than in the reported randomized clinical trials. The available data suggest that longer follow-up times and a larger sample size are required in... Read more
Published on: 2020-09-21
Source: Wimberger Pauline
By: Andreas Schneeweiss
CONCLUSIONS: In clinical practice, CDK4/6i + ET has been rapidly implemented. A group of patients with a more unfavorable prognosis was possibly treated in the real-world setting than in the reported randomized clinical trials. The available data suggest that longer follow-up times and a larger sample size are required in... Read more
Published on: 2020-09-21
Source: Wimberger Pauline
By: Andreas Schneeweiss
CONCLUSION: Although the use of PARP inhibitors is a huge step forward, it is apparent that patients, both with and without BRCA-mutant ovarian cancer, will eventually become resistant to PARP inhibitors. Therefore, novel combination therapies may enhance PARP inhibitor efficacy and overcome resistance mechanisms.... Read more
Published on: 2020-08-25
Source: Wimberger Pauline
By: Daniel Martin Klotz
CONCLUSION: Our in vitro findings point to promising anti-tumor effects of statins and zoledronic acid in ovarian cancer and warrant additional validation in preclinical and clinical settings.... Read more
Published on: 2020-07-31
Source: Wimberger Pauline
By: Andy Göbel

Other Resources

Other Citations

Other Citations

News by Specialization

News by Specialization

Videos

Selection of Videos by Specialization

Latest News

Latest News

Translate »